About Immuneel
Immuneel is a Healthcare company based in Bengaluru (India) founded in 2018 by Siddhartha Mukherjee and Kiran Mazumdar Shaw. T-cell therapies for cancer treatment are developed using genetic engineering. It operates on a HealthTech model. Immuneel has raised $49.84 million across 5 funding rounds from investors including Kotak Mahindra Bank, Apollo Hospitals and Syngene. The company has 96 employees. Immuneel was last valued at $70.46 million in June 2024. Its Indian entity Immuneel Therapeutics Private Limited reported revenue of ₹2.25 Cr. Immuneel offers products and services including CAR-T Cell Therapy. Its focus areas include Biotechnology and Cell and Gene Therapy.
Company details
Immuneel Therapeutics is dedicated to making breakthrough cancer treatments, such as cell and gene therapies including CAR-T cell therapy, accessible and affordable in India. The company operates within the healthcare and biotechnology sector, addressing the critical gap in access to next-generation cancer care. Efforts are made to serve Indias growing cancer burden while contributing to the global landscape of innovative therapies. Collaboration with global partners is emphasized to develop and deliver high-quality treatments. The mission is to improve patient outcomes and expand access to advanced medical solutions across the region and beyond.
- Headquarters Bengaluru, India
- Employees 96
- Founders Siddhartha Mukherjee, Kiran Mazumdar Shaw
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website immuneel.com
- Social LinkedIn
- Legal Name Immuneel Therapeutics Private Limited
- Date of Incorporation 20 Dec, 2018
- Jurisdiction Bengaluru, Karnataka, India
- Annual Revenue₹2.25 Cr
FY 2024 · -47% YoY
- Net Loss-₹53.77 Cr
FY 2024 · -2395% margin
- EBITDA-₹47.53 Cr
FY 2024 · -2117% margin
- Total Equity Funding$49.84M (USD)
in 5 rounds
- Latest Funding Round$10.5M (USD), Series B
Jun 2026
- InvestorsKotak Mahindra Bank
& 20 more
- Employee Count96
Associated legal entities of Immuneel
Immuneel operates through Immuneel Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Immuneel Therapeutics Private Limited CIN U24230KA2018PTC119691 | Active | 20 Dec 2018 | Bengaluru, Karnataka | ₹2.2 Cr | 96 | 6 | View details |
Products & Services of Immuneel
Immuneel offers a comprehensive portfolio of products and services, including CAR-T Cell Therapy.
Genetically modified immune cells are used to fight cancer.
Funding Insights of Immuneel
Immuneel has successfully raised a total of $49.84M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $10.5 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.84M
- Total Rounds 5
- Last Round Series B — $10.5M
- First Round $11.01M
(Nov 2019)
- Investors Count 21
All 5 funding rounds of Immuneel with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $10.5M | Series B | – | – | |
| Jun 2024 | $11.98M | Series A | $70.46M | – | |
| Apr 2022 | $15M | Series A | $53.34M | Eight Roads Ventures, True North Venture Partners | |
| Sep 2020 | $1.36M | Series A | $••••• | Pankaj R Patel | |
| Nov 2019 | $11.01M | Series A | $••••• | Khosla Ventures, Syngene |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2024 | $70.46M | •••••••• |
| Apr 2022 | $53.34M | •••••••• |
| Sep 2020 | $••••• | •••••••• |
| Nov 2019 | $••••• | •••••••• |
Full valuation and stage history of Immuneel
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $70.46M (Jun 2024). 21 investors in total: 17 institutional and 4 angel.
Investors in Immuneel
Immuneel has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Apollo Hospitals and Syngene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Early stage VC firm investing in the US | truenorthvp.com | Phoenix, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Private equity is invested by True North in mid-market companies. | truenorth.co.in | Mumbai, India | ||
| singularityamc.com | ||||
| rainmatter.com | ||||
Delivers personalized patient care, medicines, treatments, and health management in Oman. | 1997 | taibahealthcare.com | Muscat, Oman |
Investor details for Immuneel
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Immuneel Therapeutics Private Limited (Immuneel)
Immuneel Therapeutics Private Limited is the primary company behind Immuneel. The board of Immuneel Therapeutics Private Limited currently have 6 directors; the longest-serving is Kiran Mazumdar Shaw, appointed in 2018. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kiran Mazumdar Shaw DIN 00347229 | Director | 20 Dec 2018 | 7 yrs 10 mo | Immuneel Therapeutics Private Limited |
| Ranjan Ramdas Pai DIN 00863123 | Director | 20 Dec 2018 | 7 yrs 10 mo | Immuneel Therapeutics Private Limited |
| Siddhartha Mukherjee DIN 09548701 | Director | 20 Apr 2022 | 4 yrs 6 mo | Immuneel Therapeutics Private Limited |
| Prem Venkatachalam Pavoor DIN 05268309 | Director | 20 Apr 2022 | 4 yrs 6 mo | Immuneel Therapeutics Private Limited |
| Saif Khalfan Mohamed Al Hasani DIN 10754604 | Director | 29 Aug 2024 | 2 yrs 2 mo | Immuneel Therapeutics Private Limited |
| Amit Mookim DIN 07627928 | Director | 06 Sep 2024 | 2 yrs 2 mo | Immuneel Therapeutics Private Limited |
People of Immuneel
13 people are tracked at Immuneel (3 in leadership, 10 in team); the tracked headcount is 96.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder | Leadership | |
Lakshmikanth Gandikota | Head R&d, Innovation, Process And Analytics, Intellectual Property, And Translational Research | Leadership |
Akhil Agarwal | Commercial | Team |
Dhivya Bharathi Jb | Scientist- Innovation & Discovery | Team |
Nikhil Chipli | Analyst | Team |
Rakesh Reddy | Scientist -analytical Development | Team |
Alex P. Jose | Scientist- Translational Research | Team |
Rahul Nahar | Translational Research Scientist | Team |
Nitha Paul | Human Capital | Team |
Dr. Gowri Shankar Krishnan | Research Scientist - Translational Research | Team |
Giridharan Appaswamy | Process Developer | Team |
Omkar Patil | Scientist | Team |
Complete people profiles for Immuneel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Immuneel
Figures of Immuneel Therapeutics Private Limited, the primary company behind Immuneel, for FY 2024. Revenue was ₹2.25 Cr (-47% year on year). Net loss was -₹53.77 Cr (-2395% margin). EBITDA was -₹47.53 Cr (-2117% margin). Revenue has grown at a compounded annual rate of -10% over three years.
- ₹2.25 CrRevenue · FY 2024 · -47% YoY
- -₹53.77 CrNet loss · -2395% margin
- -₹47.53 CrEBITDA · -2117% margin
- ₹2.8 LakhPaid-up capital
- 96Employees (provident fund records)
- -10%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Immuneel Therapeutics Private Limited are on its company page.
Detailed financial statements for Immuneel
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Immuneel
4 dated milestones of Immuneel across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Immuneel is founded.
- Funding First funding round of $11.0M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $10.5M.
Web traffic of Immuneel
The website of Immuneel (immuneel.com) receives about 8.3K visits a month.
- Monthly visits8.3K
▲ 5.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immuneel
Complete news archive for Immuneel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immuneel
Immuneel was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Immuneel is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Immuneel is a funded company, having raised a total of $49.84M across 5 funding rounds to date. The company's 1st funding round was a Series A of $11.01M, raised on Nov 2019.
Immuneel has 96 employees.
The primary company behind Immuneel, Immuneel Therapeutics Private Limited, reported revenue of ₹2.25 Cr for FY 2024, down 47% year on year.
Immuneel Therapeutics is dedicated to making breakthrough cancer treatments, such as cell and gene therapies including CAR-T cell therapy, accessible and affordable in India. The company operates within the healthcare and biotechnology sector, addressing the critical gap in access to next-generation cancer care. Efforts are made to serve Indias growing cancer burden while contributing to the global landscape of innovative therapies. Collaboration with global partners is emphasized to develop and deliver high-quality treatments. The mission is to improve patient outcomes and expand access to advanced medical solutions across the region and beyond.
Immuneel offers CAR-T Cell Therapy.
Immuneel has 21 investors. Key investors include Kotak Mahindra Bank, Apollo Hospitals, Syngene, Khosla Ventures, and Eight Roads Ventures.
The valuation of Immuneel is $70.46M as of Jun 2024.
Immuneel operates through Immuneel Therapeutics Private Limited.
The legal entities of Immuneel currently have 6 directors, including Kiran Mazumdar Shaw, Siddhartha Mukherjee, Prem Venkatachalam Pavoor and others.